Status:
TERMINATED
Flunarizine for Treatment Resistant Absence Epilepsy
Lead Sponsor:
University of British Columbia
Conditions:
Childhood Absence Epilepsy
Juvenile Absence Epilepsy
Eligibility:
All Genders
4-18 years
Phase:
PHASE2
Brief Summary
This is an open-label, single-centre study to evaluate the clinical efficacy, safety and tolerability of Flunarizine administered as adjunctive treatment in participants diagnosed with treatment resis...
Detailed Description
Flunarizine (flunarizine hydrochloride) is indicated for prophylaxis of migraine (with and without aura) in patients with frequent and severe attacks, who have not responded to other treatment and/or ...
Eligibility Criteria
Inclusion
- Participant is 4 to 18 years of age
- Participant has treatment resistant absence seizures. Treatment resistant absence seizures are defined as failure to respond to 2 or more appropriate anti-seizure medications (ASMs). The potential participant must have failed to respond to or tolerate appropriate doses of two of the following: ethosuximide (\>/= 20 mg/kg/day), Valproic acid/divalproex sodium (\>/= 15 mg/kg/day) or lamotrigine, (\>/= 5 mg/kg/day).
- Participant must currently be taking a minimum of one ASM
- Normal development (may have specific learning disabilities and/or attention deficit hyperactivity disorder/attention deficit disorder (ADHD/ADD))
- EEG confirmation of absence seizures and EEG within 2 months of screening visit
- Absence seizures reported at least 10 times per week
- Participants must have no changes in baseline ASMs for 1 month prior to screening period
- Participant or caregiver can maintain a seizure diary
- Participant is able to swallow capsules
- Written informed consent must be provided. Legal guardians of the participants must be able to understand and provide written consent on behalf of the participant, since study participants may be too young to provide informed consent. For participants 7-18 years of age, assent will be required along with written informed consent of the caregiver.
- The participant is willing and able to attend all study visits at British Columbia (BC) Children's Hospital
- Participant has the ability to speak and read in English
- Females of child bearing potential who are sexually active must be willing to use contraceptive methods for the duration of the study and 6 months post last dose of study drug.
- Males who are sexually active with females of child bearing potential must be willing to use contraception for the duration of the study and 3 months post last dose of study drug.
Exclusion
- Age \< 4 years, \> 18 years
- Participant has uncontrolled myoclonic or generalized tonic clonic seizures
- Psychogenic non-epileptic seizures
- Known diagnosis of intellectual disability
- Autism spectrum disorder
- Participant is taking carbamazepine, oxcarbazepine, phenytoin, eslicarbazepine, or vigabatrin
- History of poor compliance with medication
- Inability of parent or caregiver to maintain a seizure diary
- History of depression or psychosis
- Participant has previously taken flunarizine and has had an adverse reaction to treatment
- Participants who are pregnant or breastfeeding,
- Presence of extrapyramidal symptoms
- Participants who have clinically significant hepatic impairment as assessed by the investigator
- Participants with known hypersensitivity to flunarizine or any of its ingredients
Key Trial Info
Start Date :
September 20 2019
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
May 26 2023
Estimated Enrollment :
9 Patients enrolled
Trial Details
Trial ID
NCT06153186
Start Date
September 20 2019
End Date
May 26 2023
Last Update
December 1 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
BC Children's Hospital
Vancouver, British Columbia, Canada, V6H 3V4